These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33215343)

  • 21. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: efficacy and toxicity.
    Miglierini P; Bouchekoua M; Rousseau B; Hieu PD; Malhaire JP; Pradier O
    Clin Neurol Neurosurg; 2012 Nov; 114(9):1222-5. PubMed ID: 22464950
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Congress of neurological surgeons systematic review and evidence-based clinical practice parameter guidelines for the treatment of adults with newly diagnosed glioblastoma: Introduction and Methods.
    Olson JJ; Ryken TC
    J Neurooncol; 2020 Nov; 150(2):87-93. PubMed ID: 33215339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polymeric drug delivery for the treatment of glioblastoma.
    Wait SD; Prabhu RS; Burri SH; Atkins TG; Asher AL
    Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii9-ii23. PubMed ID: 25746091
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
    Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
    J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.
    Gutenberg A; Lumenta CB; Braunsdorf WE; Sabel M; Mehdorn HM; Westphal M; Giese A
    J Neurooncol; 2013 Jun; 113(2):163-74. PubMed ID: 23535992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme.
    Barrié M; Couprie C; Dufour H; Figarella-Branger D; Muracciole X; Hoang-Xuan K; Braguer D; Martin PM; Peragut JC; Grisoli F; Chinot O
    Ann Oncol; 2005 Jul; 16(7):1177-84. PubMed ID: 15857844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review.
    Dixit S; Hingorani M; Achawal S; Scott I
    Br J Neurosurg; 2011 Aug; 25(4):459-69. PubMed ID: 21344976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCNU wafer placement with temozolomide (TMZ) in the immediate postoperative period after tumor resection followed by radiation therapy with TMZ in patients with newly diagnosed high grade glioma: final results of a prospective, multi-institutional, phase II trial.
    Burri SH; Prabhu RS; Sumrall AL; Brick W; Blaker BD; Heideman BE; Boltes P; Kelly R; Symanowski JT; Wiggins WF; Ashby L; Norton HJ; Judy K; Asher AL
    J Neurooncol; 2015 Jun; 123(2):259-66. PubMed ID: 25947286
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of cytotoxic chemotherapy in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.
    Olson JJ; Nayak L; Ormond DR; Wen PY; Kalkanis SN;
    J Neurooncol; 2014 Jul; 118(3):501-55. PubMed ID: 24740194
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Surgery in the Management of Adults With Metastatic Brain Tumors.
    Nahed BV; Alvarez-Breckenridge C; Brastianos PK; Shih H; Sloan A; Ammirati M; Kuo JS; Ryken TC; Kalkanis SN; Olson JJ
    Neurosurgery; 2019 Mar; 84(3):E152-E155. PubMed ID: 30629227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
    Wang Y; Xing D; Zhao M; Wang J; Yang Y
    PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
    Chinot OL; de La Motte Rouge T; Moore N; Zeaiter A; Das A; Phillips H; Modrusan Z; Cloughesy T
    Adv Ther; 2011 Apr; 28(4):334-40. PubMed ID: 21432029
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hypo-fractionated IMRT for patients with newly diagnosed glioblastoma multiforme: a 6 year single institutional experience.
    Ciammella P; Galeandro M; D'Abbiero N; Podgornii A; Pisanello A; Botti A; Cagni E; Iori M; Iotti C
    Clin Neurol Neurosurg; 2013 Sep; 115(9):1609-14. PubMed ID: 23453151
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congress of Neurological Surgeons systematic review and evidence‑based guidelines on the management of recurrent diffuse low-grade glioma: update.
    Morrow K; Sloan A; Olson JJ; Ormond DR
    J Neurooncol; 2024 Oct; ():. PubMed ID: 39400661
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma.
    Narayana A; Gruber D; Kunnakkat S; Golfinos JG; Parker E; Raza S; Zagzag D; Eagan P; Gruber ML
    J Neurosurg; 2012 Feb; 116(2):341-5. PubMed ID: 22035272
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.
    Kong XT; Nguyen NT; Choi YJ; Zhang G; Nguyen HN; Filka E; Green S; Yong WH; Liau LM; Green RM; Kaprealian T; Pope WB; Nghiemphu PL; Cloughesy T; Lassman A; Lai A
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1195-1203. PubMed ID: 29722661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Impact of angiogenic inhibition in the treatment of newly diagnosed and recurrent glioblastoma: a meta-analysis based on randomized controlled trials.
    Lan XY; Li D; Li S; Zhong LZ; Zhao H; Xi YL; Sun ZW
    Eur Rev Med Pharmacol Sci; 2022 May; 26(10):3522-3533. PubMed ID: 35647833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The interventional effect of new drugs combined with the Stupp protocol on glioblastoma: A network meta-analysis.
    Li M; Song X; Zhu J; Fu A; Li J; Chen T
    Clin Neurol Neurosurg; 2017 Aug; 159():6-12. PubMed ID: 28514722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.